摘要
背景:异柠檬酸脱氢酶(IDH)突变启动事件定义主要的神经胶质瘤的临床和预后类,但尚未很好解释的潜在机制。当前的研究的主要目的是为了更好地理解IDH突变的潜在生物学神经胶质瘤是被基因表达谱。 方法:核糖核酸测序数据的年级II-IV神经胶质瘤中国神经胶质瘤的基因图谱(CGGA,N = 325)被用来评估IDH突变体和野生型之间的差异表达基因神经胶质瘤和构建基因表达式分类器来检测IDH突变样品具有高敏感性和特异性。分类器是独立验证RNA从癌症基因组图谱测序数据(TCGA,N = 699)、和预后价值的分类器也评估两个数据集。 结果:58-gene-pair IDH突变签名是由使用最高得分对算法。CGGA数据集,98.5%和100% IDH突变样本还预测基于突变体的基因表达在ii iii、IV神经胶质瘤年级IDH地位,分别。在TCGA数据集,比例分别为99.8%和100%,分别。签名依然在多变量cox分析预后标记TCGA CGGA和数据集。 结论:与典型基因表达的特征,准确地预测IDH突变状态。这表明这些肿瘤并添加预后之间共同的生物学和生物信息不被单独突变状态。这些结果有助于临床试验的数量出现分层。RNA-seq越来越普遍和有效的神经胶质瘤的分子诊断,这种基因签名将提供一个精确的方法来预测IDH RNA-seq数据突变状态。
关键词: 神经胶质瘤
Current Molecular Medicine
Title:Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas
Volume: 17 Issue: 7
关键词: 神经胶质瘤
摘要: Background: Isocitrate dehydrogenase (IDH) mutation is the initiating event that defines major clinical and prognostic classes of gliomas, but the potential mechanisms have not been well interpreted yet. The main objective of the current study was to better understand the underlying biology of IDH mutant gliomas as captured by gene expression profiles.
Methods: RNA sequencing data of WHO grade II-IV gliomas from the Chinese Glioma Genome Atlas (CGGA, N=325) were used to assess differentially expressed genes between IDH mutant and wild type gliomas and to construct a gene expression-based classifier to detect IDH mutant samples with high sensitivity and specificity. The classifier was validated in independent RNA sequencing data from the Cancer Genome Atlas (TCGA, N=699), and the prognostic value of the classifier was also assessed in the two datasets.
Results: A 58-gene-pair IDH mutation signature was developed by using the top scoring pairs algorithm. In CGGA dataset, 98.5% and 100% IDH mutant samples were also predicted to be mutant by gene expression based IDH status in grade II-III and grade IV gliomas, respectively. In TCGA dataset, the proportions were 99.8% and 100%, respectively. The signature remained to be a prognostic marker in multivariate cox analysis both in CGGA and TCGA datasets.
Conclusion: A characteristic gene expression signature is associated with and accurately predicts IDH mutation status. This suggests a common biology between these tumors and adds prognostic and biologic information that is not captured by the mutation status alone. These results may help in population stratification for clinical trials. As RNA-seq is more and more prevalent and cost-effective in glioma molecular diagnosis, this gene signature would provide a precise method to predict IDH mutation status with RNA-seq data.
Export Options
About this article
Cite this article as:
Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas, Current Molecular Medicine 2017; 17 (7) . https://dx.doi.org/10.2174/1566524018666180212151429
DOI https://dx.doi.org/10.2174/1566524018666180212151429 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pro-Oncogenic Cell Signaling Machinery as a Target for Oncolytic Viruses
Current Pharmaceutical Biotechnology γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
Current Topics in Medicinal Chemistry Recent Advances in Superparamagnetic Iron Oxide Nanoparticles for Cellular Imaging and Targeted Therapy Research
Current Pharmaceutical Design Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Modulation of Matrix Metalloproteinases by Plant-derived Products
Current Cancer Drug Targets ExomiRs: A Novel Strategy in Cancer Diagnosis and Therapy
Current Gene Therapy Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells
Current Drug Delivery Strategies of overcoming the physiological barriers for tumor-targeted nano-sized drug delivery systems
Current Pharmaceutical Design Non Polymeric Nanoparticles for Photodynamic Therapy Applications: Recent Developments
Current Medicinal Chemistry Trichostatin A - like Hydroxamate Histone Deacetylase Inhibitors as Therapeutic Agents: Toxicological Point of View
Current Medicinal Chemistry Interrelation of Major Depression and Antidepressant Transcriptomics
Current Psychopharmacology Interlocked Systems in Nanomedicine
Current Topics in Medicinal Chemistry In vivo Evaluation and Alzheimer’s Disease Treatment Outcome of siRNA Loaded Dual Targeting Drug Delivery System
Current Pharmaceutical Biotechnology Therapeutic Potential of Targeting PAK Signaling
Anti-Cancer Agents in Medicinal Chemistry The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?
Current Medicinal Chemistry Gene Therapy Targeting in the Central Nervous System
Current Gene Therapy Role of ABC Transporters in Veterinary Medicine: Pharmaco- Toxicological Implications
Current Medicinal Chemistry DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design Lymphocytes in Alzheimer’s Disease Pathology: Altered Signaling Pathways
Current Alzheimer Research Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands
Current Medicinal Chemistry